GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Drug Utilization Study for Pirinase Hayfever Relief
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- Drug: Pirinase Hayfever Relief for Adults 0.05% Nasal Spray
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT02856282
- Locations
- 🇬🇧
GSK Investigational Site, Brentford, United Kingdom
To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.
Phase 1
Completed
- Conditions
- Infections, Bacterial
- Interventions
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT02853435
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
Phase 4
Completed
- Conditions
- TetanusPoliomyelitisHepatitis BDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b VaccinesDiphtheriaAcellular PertussisHaemophilus Influenzae Type b
- Interventions
- Biological: Infanrix hexa
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 551
- Registration Number
- NCT02853929
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT02849418
- Locations
- 🇯🇵
GSK Investigational Site, Yamanashi, Japan
A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.
Phase 1
Completed
- Conditions
- Motion Sickness
- Interventions
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 128
- Registration Number
- NCT02839135
- Locations
- 🇨🇦
GSK Investigational Site, Mont Royal, QC, Quebec, Canada
Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.
Not Applicable
Completed
- Conditions
- Infections, Streptococcal
- Interventions
- Other: BAL fluid samplingOther: Nasopharyngeal swab sampling
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 197
- Registration Number
- NCT02838407
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Phase 3
Completed
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- Drug: Placebo matching OCS capsules
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 108
- Registration Number
- NCT02836496
- Locations
- 🇬🇧
GSK Investigational Site, Leicester, United Kingdom
A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: FFDrug: VI/UMEC
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT02837380
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Effect of the GSK2245035 on the Allergen-induced Asthmatic Response
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo Nasal Spray Solution
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT02833974
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT02832362
- Locations
- 🇨🇦
GSK Investigational Site, Quebec City, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath